Menu
ncarol.com
  • Home
  • Financial
  • Business
  • Education
  • Health
  • Finance
  • Nyse
  • Yacht Buyer
  • Stocks
ncarol.com

OncoBeta GmbH and Australian Nuclear Science and Technology Organisation sign Letter of Intent to establish manufacturing site in Australia
ncarol.com/10075130

Trending...
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
  • UK Financial Ltd Confirms CATEX Exchange Integration of SMPRA and LTNS 1 Ahead of Compliance-Based Trading Activation
Rhenium Sct Produced In Australia Capture Obg Press Photo 1 No Language 002 OncoBeta GmbH
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer to be produced in Australia

MUNICH - ncarol.com -- Garching n. Munich, Germany and Lucas Heights, NSW, Australia – OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma skin cancers and the Australian Nuclear Science and Technology Organisation (ANSTO), are pleased to announce that they have signed a Letter of Intent to establish manufacturing and distribution in Australia for OncoBeta's novel Rhenium-SCT® therapeutic.

ANSTO is the leader in nuclear science in Australia and has extensive experience in the manufacturing of radiopharmaceutical diagnostics, therapies and medical devices, they are the perfect partner for OncoBeta to work with to introduce the Rhenium-SCT® product to Australia. Together, the parties will achieve a key milestone, bringing the production of Rhenium-SCT® closer to Australians suffering of non-melanoma skin cancer. OncoBeta is currently in the process of securing Australian Market Approval for its product.

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. It is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Non-melanoma skin cancer is the most common type of cancer in Australia with over 500,000 people each year being diagnosed with one or more of these cancers.

ANSTO General Manager Business Development and Commercialization, Rosanne Robinson stated, "ANSTO is proud to partner with OncoBeta to establish local manufacturing of Rhenium-SCT® and to continue delivering on our core mission of improving the health of Australians and supporting industry. ANSTO has a long-standing relationship with OncoBeta and look foward Australian patients having access to their innovative therapy for non-melanoma skin cancers. OncoBeta will join our growing nandin innovation community, focussed on attracting entrepreneurs, early stage start-ups and innovative companies who want to leverage the opportunity to be co-located with ANSTO and to access our unique expertise in the nuclear industry."

More on ncarol.com
  • Ashikaga Flower Park's "Great Wisteria Festival 2026"
  • Architect of Neurodiversity Will Lead the First U.S. Team of Autistic Children to the "Genius Cup" in Hiroshima, Japan, in 2027
  • Deborah E. Jones Introduces Emotional Sovereignty, a Powerful New Book on Emotional Mastery, Resilience, and Intentional Living
  • New Research Identifies "The Busy Effect": 89% of Americans Want a Laid-Back Vacation — Only 15% Actually Achieve It
  • Alchemy 43 Appoints Shane Smith as CEO to Drive Operational Performance and Scalable Growth

Nicholas H. Vetter, Chief Operating Officer of OncoBeta® GmbH stated: "We are incredibly excited to start extending our production footprint to Australia. It's a great pleasure to work towards solidifying a partnership with ANSTO so we can do our jobs: to bring the Rhenium-SCT® to large patient populations suffering of non-melanoma skin cancer. With this partnership we can finally move beyond trying to service the market from our other production sites in Europe or South Africa. It's a perfect time to expand our business."

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About ANSTO

ANSTO leverages great science to deliver big outcomes. We partner with a broad range of industry partners to apply new technologies to provide real-world benefits. Our work improves human health, saves lives, builds our industries and protects the environment.  ANSTO is the home of Australia's most significant landmark and national infrastructure for research. Thousands of scientists from industry and academia benefit from gaining access to state-of-the-art instruments every year.

More on ncarol.com
  • New from Regal House Publishing, Pinkie's Turnabout, a girl fights to adopt a cat to save her
  • Best Spiritual Healing, Meditation & Retreats in Sedona — Rise Meditation Helps You Find and Book Transformational Experiences
  • $16 Billion Market by 2034 in Underwater Drones Presents Huge Opportunity for AI-Powered Autonomous Vehicle Serving Defense & Commercial Customers
  • Appliance EMT Named Among Jacksonville's Top 3 Appliance Repair Companies by ThreeBestRated®
  • 3rd Annual Meditative Melodies Event Brings Global Arts and Guided Wellness to Charlotte on April 18

For more information visit www.ansto.gov.au

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/

Facebook: https://www.facebook.com/oncobeta/

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact
OncoBeta GmbH
info@oncobeta.com
+49 (89) 5484224 0


Source: OncoBeta GmbH
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • FinIQ Edu Launches High-Impact Workshop Vertical to Close the Workplace Benefits Gap—Drives 82% Surge in 401(k) Participation Intent
  • HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
  • J&J Exterminating Reminds Residents to prepare for Termite Swarm Season
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • Charlotte-based PR Founder + Expert Launches New Website Highlighting Brand Astrology™ Methodology
  • Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
  • IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
  • AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
  • Surging Into Hyper-Growth Mode With Record Revenue, Raised 2026 Guidance, and Game-Changing AI Platform; Off The Hook YS (NYSE American: OTH)
  • Mom Creators Coalition Launches with WaterWipes® as Official Founding Sponsor
  • PandaGuarantee Launches Rent Guarantor Service in New York City
  • The $112M Marketing Lesson Joe Whyte Learned: Why 'More Traffic' Is the Biggest Lie in Digital Marketing
  • Daniel Kaufman Expands Kaufman & Company Real Estate Platform With New Acquisitions, AI-Driven Industrial Development and Nationwide Growth Initiative
  • Sherwood Manufactured Home Community Launches Historic Spring Savings Event
  • purelyIV Launches Lab Testing Services in Metro Detroit
  • On the 296th Anniversary of the Ceremony That Made His Ancestor Emperor, a Cherokee Descendant Publishes the Novel That Restores Him
  • NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
  • Nufabrx Added to TrillaMed Pharmacy and DAPA Contracts
  • DC Accounting Firm Offers Free Business CRM to Small Business Clients Alongside Weekly Bookkeeping Model
  • CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
_catLbl0 _catLbl1

Popular on ncarol.com

  • Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services - 105
  • Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
  • Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
  • Elder Abuse Case Against Healthy Traditions Owner Raises Questions As To The Dire Reality Of Abuse Against The Last Of The Baby Boomers
  • Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption
  • Pure Energy Electrical Services, LLC Announces Strong Start to 2026, Reinforcing Customer-First Electrical Service Across Northeast Florida
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
  • Notice: Hrm Queen Laurence I Assumes Crown Control & $317q Fund. 3bn Unopoly Shares Settled. Requisition Of Buckingham Palace & Windsor Castle Final
  • Heritage at Manalapan Introduces New Single-Family Home Community in One of Monmouth County's Most Desirable Locations

Similar on ncarol.com

  • Architect of Neurodiversity Will Lead the First U.S. Team of Autistic Children to the "Genius Cup" in Hiroshima, Japan, in 2027
  • Deborah E. Jones Introduces Emotional Sovereignty, a Powerful New Book on Emotional Mastery, Resilience, and Intentional Living
  • Alchemy 43 Appoints Shane Smith as CEO to Drive Operational Performance and Scalable Growth
  • Best Spiritual Healing, Meditation & Retreats in Sedona — Rise Meditation Helps You Find and Book Transformational Experiences
  • $16 Billion Market by 2034 in Underwater Drones Presents Huge Opportunity for AI-Powered Autonomous Vehicle Serving Defense & Commercial Customers
  • 3rd Annual Meditative Melodies Event Brings Global Arts and Guided Wellness to Charlotte on April 18
  • Kiko Nation Expands to Apple App Store, Achieving Full Mobile Deployment for Livestock Digital Registry Platform
  • The Lawyers' Marketer Launches Claude AI Implementation Service for Law Firms
  • HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
  • IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute